StockData
Valion Bio, Inc. logo

Valion Bio, Inc. (VBIO) stock

VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.54+0.01 (+2.72%)

Close on Nov 17, 2026Market cap $2.26MP/E –Yield –

Valion Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Valion Bio's revenue for the twelve months ending Sep 30, 2025 was $482.00K, down 49.6% year over year. For fiscal 2024 it was $780.00K, down 33.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$780.00K-33.7%
FY2023Dec 31, 2023$1.18M-36.1%
FY2022Dec 31, 2022$1.84M+46.4%
FY2021Dec 31, 2021$1.26M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$146.00K+15.9%
Q2 FY2025Jun 30, 2025$86.00K-38.6%
Q1 FY2025Mar 31, 2025$70.00K-79.0%
Q4 FY2024Dec 31, 2024$180.00K-49.6%
Q3 FY2024Sep 30, 2024$126.00K-55.3%
Q2 FY2024Jun 30, 2024$140.00K-13.0%
Q1 FY2024Mar 31, 2024$334.00K-11.2%
Q4 FY2023Dec 31, 2023$357.00K-12.5%
Q3 FY2023Sep 30, 2023$282.00K-40.9%
Q2 FY2023Jun 30, 2023$161.00K-69.5%
Q1 FY2023Mar 31, 2023$376.00K-12.1%
Q4 FY2022Dec 31, 2022$408.00K+4.9%
Q3 FY2022Sep 30, 2022$477.00K+72.2%
Q2 FY2022Jun 30, 2022$528.00K+97.0%
Q1 FY2022Mar 31, 2022$428.00K+32.5%
Q4 FY2021Dec 31, 2021$389.00K–
Q3 FY2021Sep 30, 2021$277.00K–
Q2 FY2021Jun 30, 2021$268.00K–
Q1 FY2021Mar 31, 2021$323.00K–

More Valion Bio figures

See a number that looks wrong?